Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754484 | 0.87 | GPR119 (0.54) | GPR119CNR2KMT2ALMNAL3MBTL1 | |
| SCHEMBL2155090 | 0.83 | AKR1C3 (0.52) | SMOKMT2AABL1BCRLMNA | |
| SCHEMBL15450910 | 0.83 | GPR119 (0.58) | GPR119NPSR1SMOKMT2ALMNA | |
| SCHEMBL3934328 | 0.81 | ME2 (0.49) | SMOKMT2ALMNARETL3MBTL1 | |
| SCHEMBL5916430 | 0.81 | LMNA (0.49) | GPR119SMOKMT2AABL1BCR | |
| SCHEMBL2254910 | 0.81 | LMNA (0.49) | GPR119SMOKMT2AABL1BCR | |
| SCHEMBL14349677 | 0.80 | RORC (0.51) | SMOKMT2ALMNANPC1RAB9A | |
| SCHEMBL12755246 | 0.79 | GAA (0.52) | GPR119SMOKMT2ALMNAL3MBTL1 | |
| SCHEMBL2959440 | 0.79 | CHRM4 (0.66) | GPR119KMT2AL3MBTL1ALDH1A1TSHR | |
| SCHEMBL6125262 | 0.78 | KMT2A (0.58) | GPR119CNR2KMT2ARAB9APANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101124213-B | Sulfonylamino cyclic derivatives and uses thereof | MERCK SERONO S.A. (CH) | 2012-02-01 | — | — | CN | disclosed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| CN-1418197-A | Piperidine and piperazine substituted N-hydroxycarboxamides as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | CN | disclosed |
| CN-1404474-A | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-03-19 | — | — | CN | disclosed |
| EP-1261595-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062751-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | GPR119 2869/4885NPSR1 1826/4885CNR2 4399/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | GPR119 2869/4885NPSR1 1826/4885CNR2 4399/4885 |
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | GPR119 864/4885NPSR1 489/4885CNR2 567/4885 |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | GPR119 80/4885NPSR1 1212/4885CNR2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.